Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples